` 1AD (Adalta Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

1AD
vs
S
S&P/ASX 300

Over the past 12 months, 1AD has underperformed S&P/ASX 300, delivering a return of -76% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
1AD vs S&P/ASX 300

Loading
1AD
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
1AD vs S&P/ASX 300

Loading
1AD
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
1AD vs S&P/ASX 300

Loading
1AD
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Adalta Ltd vs Peers

S&P/ASX 300
1AD
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Adalta Ltd
Glance View

Market Cap
6.9m AUD
Industry
Biotechnology

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company’s lead candidate AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target. The i-body has also demonstrated its usefulness in treating fibrosis of the eye and is being pursued as an additional opportunity for the treatment of age-related macular degeneration (wet-AMD). The i-body is identified to have affinity and specificity with a drug target of interest, its effectiveness is evaluated in cell-based assays (in vitro) and in animal experiments (in vivo).

1AD Intrinsic Value
0.004 AUD
Undervaluation 19%
Intrinsic Value
Price
Back to Top